posted on
Aug 25, 2021 11:20AM
...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Message: Re: Trillium
fouremm, congrats on your win with Trillium.
It's a good example of the value that exists if the business side is competent. I've often used the example of Loyd Segal at Repare Therapeutics. Each wave of investors was rewarded along the way with the big payout comming from the NASDAQ listing at $20USD that quickly moved up to $30+USD. And all of this without drugs on the market.
Don does not seem to understand the concept of rewarding investors. In fact I'm convinced he does not understand much of anything.
I've been hoping for some liquidity on ZCC or ZE shares. The Repare NASDAQ was done with the full fanfair of NASDAQ. A reverse takeover of a NASDAQ listed company would not have the same profile but, frankly, at this stage of disappointment, I'll take anything.
It's been almost 2 years since the BoM results were announced and Don has not come up with a BoM2 trial partner. What does he do all day? Is he still functional? Why does Hepa keep him in there? It is a head scratcher for sure. I keep hoping for some good news but my hope is fading.
GLTA
Toinv
5 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply